BioCentury | Jan 15, 2020
Clinical News

Denali gains on Parkinson’s results as it looks to select a Phase II candidate

...San Francisco. In PD, lysosomal dysfunction is linked to inflammation and neuronal loss. Denali said DNL201...
...Phase Ib testing of DNL151 in PD patients will be expanded to include higher doses. DNL201...
...late 2020. Targets: IDS - Iduronate 2-sulfatase; LRRK2 - leucine-rich repeat kinase 2 Hongjiang Li, Staff Writer DNL151 DNL201 Denali...
BioCentury | Aug 23, 2018
Translation in Brief

LRRK2 looming larger

...the company announced completion of a Phase I trial of its small molecule LRRK2 inhibitor DNL201...
...said the biomarkers will allow Denali to identify patients for planned Phase Ib trials of DNL201...
BioCentury | May 17, 2018
Translation in Brief

A LRRK-ing link

...least three LRRK2 inhibitors are in development for PD, the most advanced of which is DNL201...
BioCentury | Dec 22, 2017
Clinical News

FDA lifts hold on Denali PD candidate

...FDA lifted a partial clinical hold on a Phase I study of Parkinson's disease candidate DNL201...
...agency placed the hold to impose an exposure cap that only allowed Denali to test DNL201...
...Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) granted Denali exclusive, worldwide rights to LRRK2 inhibitors, including DNL201...
BioCentury | Dec 21, 2017
Clinical News

FDA lifts hold on Denali's PD candidate

...FDA lifted a partial clinical hold on a Phase I study of Parkinson's disease candidate DNL201...
...on preclinical toxicity data to impose an exposure cap that only allowed Denali to test DNL201...
...Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) granted Denali exclusive, worldwide rights to LRRK2 inhibitors, including DNL201...
BioCentury | Dec 14, 2017
Financial News

Denali raises $250M in IPO

...Sept. 5, 2016 ). The company's lead candidates include leucine-rich repeat kinase 2 (LRRK2) inhibitors DNL201...
...RIP1) inhibitor DNL747, which Denali is developing to treat Alzheimer's disease and amyotrophic lateral sclerosis. DNL201...
...I trial of DNL747 in healthy volunteers. Denali Therapeutics Inc. (NASDAQ:DNLI), South San Francisco, Calif. Allison Johnson DNL151 DNL201 DNL747 Denali...
BioCentury | Dec 8, 2017
Financial News

Denali climbs after $250M IPO

...Sept. 12, 2016) . The company's lead candidates include leucine-rich repeat kinase 2 (LRRK2) inhibitors DNL201...
...RIP1) inhibitor DNL747, which Denali is developing to treat Alzheimer's disease and amyotrophic lateral sclerosis. DNL201...
...Next half, Denali plans to start a Phase I trial of DNL747 in healthy volunteers. Allison Johnson DNL151 DNL201 DNL747 Denali...
BioCentury | Nov 17, 2017
Financial News

Neurology play Denali planning $100M IPO

...DNL201 and DNL151, and receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitor DNL747. Parkinson’s disease candidate DNL201...
...tau) (MAPT) (FTDP-17) Receptor-interacting serine-threonine kinase 1 (RIPK1) (RIP1) Triggering receptor expressed on myeloid cells 2 (TREM2) amyloid beta ATV:aSYN ATV:BACE1/Tau ATV:TREM2 DNL151 DNL201 DNL747 ETV:IDS...
BioCentury | Nov 15, 2017
Financial News

Neurology play Denali planning $100M IPO

...DNL201 and DNL151, and receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitor DNL747. Parkinson’s disease candidate DNL201...
...tau) (MAPT) (FTDP-17) Receptor-interacting serine-threonine kinase 1 (RIPK1) (RIP1) Triggering receptor expressed on myeloid cells 2 (TREM2) amyloid beta ATV:aSYN ATV:BACE1/Tau ATV:TREM2 DNL151 DNL201 DNL747 ETV:IDS...
Items per page:
1 - 9 of 9